Načítání...

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

RTTNews | Před 671 dny

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.

With today's closing, Regeneron will now record 100% of global net sales and expenses for Libtayo.

Regeneron intends to update its full year 2022 financial guidance to reflect the Libtayo purchase during its second quarter 2022 earnings announcement in early August.

On May 31, 2022, Regeneron announced that it had successfully acquired Checkmate Pharmaceuticals, Inc. for a total equity value of approximately $250 million.

As a result of the Checkmate acquisition, Regeneron expects to record in the second quarter of 2022 an acquired in-process research and development (IPR&D) charge of approximately $195 million, which would negatively impact GAAP and non-GAAP diluted earnings per share by approximately $1.70.

Značky : REGN SNY SNYNF

read more

Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up

Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up

French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq.

RTTNews | Před 7 dny

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

RTTNews | Před 90 dny

Sanofi Q3 Profit Rises, Backs FY23 View, To Split Consumer Healthcare Unit; Stock Dips

Sanofi Q3 Profit Rises, Backs FY23 View, To Split Consumer Healthcare Unit; Stock Dips

French drug major Sanofi reported Friday higher profit in its third quarter, while sales declined. Further, the company reiterated fiscal 2023 business earnings view. Separately, Sanofi said it plans to separate the Consumer Healthcare Business with a view to focus on Biopharma business. Sanofi shares were losing more than 15 percent in the morning trading in Paris.

RTTNews | Před 188 dny

Sanofi Q4 Profit Climbs, Sees Slower Earnings Growth In FY23; Stock Down

Sanofi Q4 Profit Climbs, Sees Slower Earnings Growth In FY23; Stock Down

French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...

RTTNews | Před 454 dny

Wall Street Looks Headed For Positive Start

Wall Street Looks Headed For Positive Start

Higher futures point to a positive start for U.S. stocks Thursday morning. The market is likely to benefit from Fed Chair Jerome Powell's comments that the next rate move from the central bank will most likely be an interest rate reduction.

RTTNews | Před 4 h 20 min

Parker Hannifin Boosts FY24 Earnings Outlook As Q3 Results Top Estimates

Parker Hannifin Boosts FY24 Earnings Outlook As Q3 Results Top Estimates

While reporting financial results for the third quarter on Thursday, Parker Hannifin Corp. (PH) raised its earnings and adjusted earnings guidance for the full-year 2024.

RTTNews | Před 4 h 22 min

AMETEK Boosts FY24 Earnings Outlook - Update

AMETEK Boosts FY24 Earnings Outlook - Update

While reporting financial results for the first quarter on Thursday, AMETEK, Inc. (AME) raised its earnings and adjusted earnings guidance for the full-year 2024, while maintaining annual net sales growth outlook.

RTTNews | Před 4 h 45 min

Moody's Narrows FY24 Outlook Range - Update

Moody's Narrows FY24 Outlook Range - Update

While reporting financial results for the first quarter on Thursday, Moody's Corp. (MCO) narrowed its earnings, adjusted earnings and revenue growth guidance range for the full-year 2024.

RTTNews | Před 5 h 3 min

Podmínky | Ochrana osobních údajů | Mapa stránek | Site Map Calendar

& copy; 2024 Myfxbook Ltd. Všechna práva vyhrazena.

UPOZORNĚNÍ NA VYSOKÉ RIZIKO: Obchodování s devizami přináší vysokou úroveň rizika, které nemusí být vhodné pro všechny investory. Páka vytváří další rizika a ztráty. Než se rozhodnete obchodovat s devizami, důkladně zvažte své investiční cíle, úroveň zkušeností a toleranci vůči riziku. Můžete přijít o část nebo všechny své počáteční investice. Neinvestujte peníze, které si nemůžete dovolit ztratit. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všechny údaje a informace jsou poskytovány "tak, jak jsou". pouze pro informační účely a nejsou určeny pro obchodní účely nebo rady. Výkonnost v minulosti neznamená výkonnost v budoucnosti.